Skip to main content

Table 3 Surface under the cumulative ranking curve (SUCRA) data for the outcomes of mortality and severe adverse events

From: Treatment of idiopathic pulmonary fibrosis: a network meta-analysis

a. SUCRA rankings for mortality

Treatment

SUCRA

Sildenafil

0.913

Pirfenidone

0.749

Nintedanib

0.719

Imatinib

0.624

Macitentan

0.604

Bosentan

0.533

Placebo

0.490

NAC monotherapy

0.483

Ambrisentan

0.238

VKA

0.097

Triple therapy

0.050

b. SUCRA rankings for severe adverse events

Treatment

SUCRA

Bosentan

0.756

Sildenafil

0.692

Macitentan

0.684

Nintedanib

0.638

Imatinib

0.627

Pirfenidone

0.597

Placebo

0.587

NAC monotherapy

0.413

Ambrisentan

0.279

VKA

0.190

Triple therapy

0.038

  1. SUCRA, Surface under cumulative ranking curve